Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment

By Lage Maureen J.   Carroll Cathryn A.   Fairman Kathleen A.  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1146-1153

Informa Healthcare

Access to resources Recommend Favorite

Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis

By Moses Harold   Brandes David W.  

Current Medical Research and Opinion, Vol. 24, Iss. 9, 2008-09 ,pp. : 2679-2690

Informa Healthcare

Access to resources Recommend Favorite

Disease-modifying drugs in multiple sclerosis: a review of expenditure in Ireland

By Bailey B.  

Irish Journal of Medical Science, Vol. 180, Iss. 2, 2011-06 ,pp. : 337-341

Springer Publishing Company

Access to resources Recommend Favorite

Disease‐modifying treatments for multiple sclerosis – a review of approved medications

By  

EUROPEAN JOURNAL OF NEUROLOGY, Vol. 23, Iss. S1, 2016-01 ,pp. : 18-27

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison

By Hutchinson Michael   Fox Robert J.   Havrdova Eva   Kurukulasuriya Nuwan C.   Sarda Sujata P.   Agarwal Sonalee   Siddiqui Mohd Kashif   Taneja Ankush   Deniz Baris  

Current Medical Research and Opinion, Vol. 30, Iss. 4, 2014-04 ,pp. : 613-627

Informa Healthcare

Access to resources Recommend Favorite